Equities
  • Price (USD)121.61
  • Today's Change1.94 / 1.62%
  • Shares traded996.83k
  • 1 Year change14.05%
  • Beta1.3336
Data delayed at least 15 minutes, as of Oct 23 2020 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.

  • Revenue in USD (TTM)5.54bn
  • Net income in USD846.10m
  • Incorporated1992
  • Employees3.08k
  • Location
    Alexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
  • Phone+1 (475) 230-2596
  • Fax+1 (203) 271-8198
  • Websitehttps://alexion.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALXN:NSQ since
announced
Transaction
value
Portola Pharmaceuticals IncDeal completed05 May 202005 May 2020Deal completed17.11%1.46bn
Data delayed at least 15 minutes, as of Oct 23 2020 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shionogi & Co Ltd3.09bn1.11bn15.05bn5.22k13.362.0012.204.87379.11379.111,050.772,528.890.40021.385.4462,044,240.0014.4014.0115.7715.8382.8480.0135.9830.576.43--0.014925.13-9.404.00-10.9322.63-2.5314.65
Shanghai Fosun Pharmaceutical (Group)4.25bn526.62m19.13bn31.37k40.794.33--4.501.371.3711.1312.890.36973.025.99906,616.104.986.087.609.1056.4057.0313.4816.560.7985--0.381430.1914.7218.9122.669.4728.766.85
Merck KGaA20.00bn1.68bn19.54bn57.52k39.163.164.880.97713.273.2438.9341.360.40591.964.79296,724.903.414.194.535.5561.9965.058.4010.490.6146.270.438710.238.877.2920.632.2310.345.39
Otsuka Holdings Co Ltd13.55bn1.39bn21.48bn32.99k15.341.219.891.58263.09263.092,619.583,331.030.54722.583.8243,057,410.005.764.236.995.2068.3266.8110.527.991.91--0.113452.458.07--54.14------
Alexion Pharmaceuticals, Inc.5.54bn846.10m26.23bn3.08k32.062.5021.714.743.733.7324.8647.880.35410.86944.441,796,496.005.415.345.815.7591.5890.6615.2818.834.28--0.18860.0020.8117.4411,294.7929.634.55--
Astellas Pharma Inc12.15bn1.79bn26.39bn15.88k14.882.1110.862.1799.9099.90680.98703.500.6091.743.5480,191,270.008.9610.5612.2014.0579.1376.9514.7115.090.9896--0.253636.12-0.42140.8448-12.087.54-0.82115.92
Data as of Oct 23 2020. Currency figures normalised to Alexion Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

40.01%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202015.98m7.29%
BlackRock Fund Advisorsas of 30 Jun 202012.83m5.85%
Fidelity Management & Research Co. LLCas of 30 Jun 202011.36m5.18%
SSgA Funds Management, Inc.as of 30 Jun 202011.07m5.05%
Baker Bros. Advisors LPas of 30 Jun 20208.76m4.00%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 20207.44m3.40%
ClearBridge Investments LLCas of 30 Jun 20206.90m3.15%
Columbia Management Investment Advisers LLCas of 30 Jun 20205.07m2.31%
Renaissance Technologies LLCas of 30 Jun 20204.48m2.04%
Geode Capital Management LLCas of 30 Jun 20203.79m1.73%
More ▼
Data from 30 Jun 2020 - 30 Jun 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.